MIRA
INFORM REPORT
|
Report Date : |
28.05.2007 |
IDENTIFICATION DETAILS
|
Name : |
|
|
|
|
|
Registered Office : |
S-54, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
1985 |
|
|
|
|
Legal Form : |
Proprietorship |
|
|
|
|
Line of Business : |
Manufacture &
Marketing of Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
Business Name
Full Address
|
Registered Address
& Factory |
|
S-54, |
|
Tel |
92 (21) 2354695,
2354696, 2354697, 2354698 |
|
Fax |
92 (21) 2354700 |
|
|
Short Description Of
Business
|
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
Year Established |
1985 |
|
National Tax # |
1000354 |
Branches
In
Legal Status
Subject Company was established as a Proprietorship business in 1985
Details of Proprietor
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Saleh Muhammad Memon |
Pakistani |
S-54, |
Business |
Proprietor |
Associates
Subsidiary
None
Associated Companies
- Do -
Products
(1) Subject Company is engaged in manufacture & marketing of Pharmaceutical Products.
(2) It purchases raw material against L/C, T.T. basis
(3) It sells against Cash / Credit Terms.
(4) Its’ major customers are Distributors, Traders, Pharmacies
& Hospitals located in
(5) Subject operates from caption leased factory premises of area measuring 2,500 Sq.Yard. which is situated in industrial area.
(6) Subject employs about 125 persons in its set up.
Products
ACOZINE, ASPIRIN, BELLABARBITONE, BENZYL BENZOATE, BINAPLEX, CALCIUM LACTATE TABS, CARMINATIVE MIXTURE, CEFLEX, CELIMO, CHLOROQUINE, CHLOROQUINE, CHLORPHENIRAMINE, DIACRON, DIHYDRANIL, EXCOLD, FLOXON, FOLIC ACID, GENTIAN VIOLET, GRIFULVIN, ICHTHAMOL GLYCERINE, INDACIN, LYSOL, MALAKIL, MAOLAX, MELAMINE, METRONIDAZOLE, MULTIVITAMIN DROPS, PAINOL, PANDONA, PEMOXIN, PEXOCITRAL, PEXOCYCLINE, PEXOL, PEXOLECITHINE, PEXOPEN, PEXOVIT, PHENIRAL, PROMETHAZINE ELIXIR, ROXENOL, RUMATOFEN, SULPHATRAN, TROCIN, VIBRADOXIN, VIBRODOXIN
Annual Sales Volume
|
Year |
In Pak Rupees
|
|
2005 |
70,000,000/-
(Estimated) |
Capacity &
Production
The capacity and production of the company’s plant is indeterminable as it is multi- product and involves various processes of manufacture.
Authorized
Distributors
Mainly in
Bankers and their
addresses
Habib Bank Limited,
Habib Bank Limited, S.I.T.E. Branch,
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 60.93 |
|
UK Pound |
1 |
Rs. 122.55 |
|
Euro |
1 |
Rs. 81.65 |
Memberships
Comments
Subject Company was established in 1985 and is engaged in
manufacture & marketing of Pharmaceutical Products.
Trade relations are reported as fair. The Company can be considered for
normal business dealings at usual trade terms and conditions.
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit consideration.
Capability to overcome financial difficulties seems comparatively below
average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)